Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication

Vaccine

Volumn 34, Issue 10, 2016, Pages 1247-1251

  Wieten, Rosanne W ^a   Jonker, Emile F F ^b   Pieren, Daan K J ^d   Hodiamont, Caspar J ^a   van Thiel, Pieter P A M ^a   van Gorp, Eric C M ^c   de Visser, Adriëtte W ^b   Grobusch, Martin P ^a   Visser, Leo G ^b   Goorhuis, Abraham ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Immune compromised; Indirect Fluorescence Assay (IFA); Plaque Reduction Neutralization Test (PRNT); Vaccination; Yellow fever

Indexed keywords

ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; NEUTRALIZING ANTIBODY; PREDNISOLONE; YELLOW FEVER VACCINE; VIRUS ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMIZED PATIENT; IMMUNOFLUORESCENCE; PLAQUE REDUCTION NEUTRALIZATION TEST; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; SCLERODERMA; TRAVEL; VIRUS NEUTRALIZATION; YELLOW FEVER; ADULT; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DIRECT FLUORESCENT ANTIBODY TECHNIQUE; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; MIDDLE AGED; SERODIAGNOSIS; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84958740356     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.01.037     Document Type: Article

References (31)

1. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, 959-1056. Saunders/Elsevier, Philadelphie, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
2. Barrett A.D.T., Teuwen D.E. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol 2009, 21(3):308-313.
3. Poland J.D., Calishar C.H., Monath T.P., Downs W.G., Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59(6):895-900.
4. World Health Organization Meeting of the strategic advisory group of experts on immunization, April 2013-conclusions and recommendations. Weekly Epidem Rec 2013, 88(20):210-216.
5. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002, 66(5):533-541.
6. Camacho L.A., de Aguiar S.G., Freire Mda S., Leal Mda L., do Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005, 39(3):413-420.
7. Khromava A.Y., Eldex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23(25):3256-3263. Yellow Fever Vaccine Safety Working Group.
8. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(48):6077-6082.
9. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-7):1-27. Centers for Disease Control and Prevention (CDC).
10. Mateo R.I., Xiao S.Y., Travassos de Rosa A.P., Lei H., Guzman H., Lu L., et al. Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters. Am J Trop Med Hyg 2007, 77(5):919-924.
11. Kengsakul K., Sathirapongsasuti K., Punyagupta S. Fatal myelomeningoencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002, 85(1):131-134.
12. Veit O., Niedrig M., Chapuis-Taillard C., Cavassini M., Mossdorf E. Immunogenicity and safety of yellow fever vaccination of 102 HIV infected patients. Clin Infect Dis 2009, 48(5):659-666.
13. Pacanowski J., Lacombe K., Campa P., Dabrowska M., Poveda J.D., Meynard J.L., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV infected patients. J Acquir Immune Defic Syndr 2012, 59(4):360-366.
14. Sidibe M., Yactayo S., Kalle A., Sall A.A., Sow S., Ndoutabe M., et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 2012, 106(7):437-444.
15. Mota L.M., Oliveira A.C., Lima R.A., Santos-Neto L.L., Tauil P.L. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop 2009, 42(1):23-27.
16. Azevedo L.S., Lasmar E.P., Contieri F.L., Boin I., Percegona L., Saber L.T., et al. Yellow fever vaccination in organ transplanted patients: is it safe?. A multicentre study. Transpl Infect Dis 2012, 14(3):237-241.
17. World Health Organization The immunological basis for immunization series. Module 8, Yellow Fever 1996, Available from 〈http://whqlibdoc.who.int/hq/1993/WHO_EPI_GEN_93.18_mod8.pdf〉 (accessed 20 July 2015).
18. World Health Organization Meeting report, WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines 2009, Available from 〈http://www.who.int/biologicals/publications/meetings/areas/vaccines/yellow_fever/YELLOW_FEVER_2009_Final_2010_Rev1.pdf〉 (accessed 20 July 2015).
19. Monath T.P., Cropp C.B., Muth D.J., Calsher C.H. Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med and Hyg 1981, 75(2):282-286.
20. Monath T.P. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol 1970, 93(2):122-129.
21. Niedrig M., Kürsteiner O., Herzog C., Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 2008, 15(2):177-181.
22. LCR Dutch national guidelines on travellers' medicine 2007, Landelijk Coordinatiecentrum Reizigersadvisering, Amsterdam.
23. Monath T.P., Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002, 34(10):1369-1378.
24. De Madrid A.T., Porterfield J.S. A simple micro-culture method for the study of group B arbovirusses. Bull World Health Organ 1969, 40(1):113-121.
25. World Health Organization Requirements for yellow fever vaccine. WHO Tech Rep Ser 1976, 594:23-49.
26. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006, 131(2):209-212.
27. Neyts J., Meerbach A., McKenna P., De Clerq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral res 1996, 30(2-3):125-132.
28. Personal correspondence, Department of Toxicology, Leiden University Medical Center.
29. Centers for Disease Control and prevention Guide to vaccine contraindications and precautions 2008.
30. Grim J., Chladec J., Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003, 42(2):139-151.
31. Domingo C., Escadafal C., Rumer L., Méndez J.A., García P., Sall A.A., et al. First international external quality assessment study on molecular and serological methods for yellow fever diagnosis. PLoS ONE 2012, 7(5):e36291.